Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morgane Cheminant

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Linmiao Jiang, Jan Walewski, et al.
The American Journal of Surgical Pathology|December 13, 2018
Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSAClémentine Sarkozy, Christiane Copie-Bergman, Diane Damotte, et al.
The Journal of Allergy and Clinical Immunology|September 7, 2023
Severe adult hemophagocytic lymphohistiocytosis (HLHa) correlates with HLH-related gene variantsCoralie Bloch, Jean Philippe Jais, Marine Gil, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 4, 2022
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patientsYann Nguyen, Adrien Flahault, Nathalie Chavarot, et al.
Hemasphere|April 21, 2020
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL NetworkDaniela Drandi, Marion Alcantara, Ichrafe Benmaad, et al.
British Journal of Haematology|March 3, 2025
A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysisPablo Mozas, Romain Ould Ammar, Loïc Chartier, et al.
Gut|November 19, 2018
NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC studyMorgane Cheminant, Julie Bruneau, Georgia Malamut, et al.
Blood Advances|January 9, 2026
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphomaEmilie Charton, Amélie Anota, Emmannuel Bachy, et al.
Blood Cancer Journal|April 24, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA studyClémentine Sarkozy, Loïc Chartier, Vincent Ribrag, et al.
Nature Medicine|October 9, 2023
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2022
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Linmiao Jiang, Jan Walewski, et al.
The American Journal of Surgical Pathology|December 13, 2018
Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSAClémentine Sarkozy, Christiane Copie-Bergman, Diane Damotte, et al.
The Journal of Allergy and Clinical Immunology|September 7, 2023
Severe adult hemophagocytic lymphohistiocytosis (HLHa) correlates with HLH-related gene variantsCoralie Bloch, Jean Philippe Jais, Marine Gil, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 4, 2022
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patientsYann Nguyen, Adrien Flahault, Nathalie Chavarot, et al.
Hemasphere|April 21, 2020
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL NetworkDaniela Drandi, Marion Alcantara, Ichrafe Benmaad, et al.
British Journal of Haematology|March 3, 2025
A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysisPablo Mozas, Romain Ould Ammar, Loïc Chartier, et al.
Gut|November 19, 2018
NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC studyMorgane Cheminant, Julie Bruneau, Georgia Malamut, et al.
Blood Advances|January 9, 2026
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphomaEmilie Charton, Amélie Anota, Emmannuel Bachy, et al.
Blood Cancer Journal|April 24, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA studyClémentine Sarkozy, Loïc Chartier, Vincent Ribrag, et al.
Nature Medicine|October 9, 2023
Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialRoch Houot, Emmanuel Bachy, Guillaume Cartron, et al.
Pageof 8